CrushSCI.com
71Average days
66Median days
25Fastest days
160Longest days
1012025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

38 days

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors

Authors
Alejandro Falcón; Gregory M. Cote; Javier Molina-Cerrillo; Axel Le Cesne; Pedro Rocha; Bruno Bockorny; David Paez; Javier Martin-Broto; Sant P. Chawla; Sara Martinez; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Javier Jimenez; Ana Custodio; Vicente Alonso-Orduña; Carlos López; Attila Kollár; Juan José Soto-Castillo; Luis Paz-AresShow moreShow less
Affiliations
1. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain; 2. Servicio de Oncología Médica, Hospital Universitario Virgen del Rocio, Seville, Spain; 3. Medical Oncology Department, Mass General Brigham Cancer Institute, Boston, USA; 4. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 5. Medical Oncology Department, Institute Gustave Roussy, Villejuif, France; 6. Medical Oncology Department, Vall d’ Hebrón University Hospital, Barcelona, Spain; 7. Medical Oncology Department, Beth Israel Deaconess Medical Center, Boston, USA; 8. Medical Oncology Department, Sant Pau, CIBERER, Barcelona, Spain; 9. Medical Oncology Department, Fundación Jiménez Díaz University Hospital General de Villalba, and Instituto deInvestigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJDUAM), Madrid, Spain; 10. Sarcoma Oncology Research Center, Santa Monica, USA; 11. Clinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain; 12. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; 13. Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain; 14. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain; 15. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 16. Medical Oncology Department, START Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain; 17. Medical Oncology Department, Hospital Universitario, Madrid, SpainShow moreShow less
Source PDF DOI Publisher page
34 days

Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis

Authors
Nihan Küçük Yılmaz; Veysel BaskınShow moreShow less
Affiliations
1. Department of Medical Pharmacology, Faculty of Medicine, Yalova University, Yalova, Turkey; 2. Department of Medical Pharmacology, Faculty of Medicine, Hitit University, Çorum, TurkeyShow moreShow less
Source PDF DOI Publisher page
34 days

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours

Authors
Rosalind Glasspool; Sarah Patricia Blagden; Michelle Lockley; Elaine McCartney; Carol Evans; Fiona Thomson; Jennifer Brown; Laura Spiers; Chantevy Pou; Liz-Anne Lewsley; Iain A. McNeish; T.R. Jeffry EvansShow moreShow less
Affiliations
1. Beatson West of Scotland Cancer Centre and School of Cancer Sciences, University of Glasgow, Glasgow, UK; 2. Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK; 3. Centre for Cancer Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK; 4. Cancer Division, University College London Hospital, London, UK; 5. Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK; 6. The Translational Pharmacology & Immunology Laboratory, School of Cancer Sciences, University of Glasgow, Glasgow, UK; 7. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UKShow moreShow less
Source PDF DOI Publisher page
37 days

Prostate cancer cells’ growth is decreased by novel MYC inhibitors

Authors
Bita Nickkholgh; Joseph McGrath; Sivanandane Sittadjody; Jay Chauhan; Kwan-Young Jung; Steven Fletcher; K. C. BalajiShow moreShow less
Affiliations
1. Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest University School of Medicine, Winston-Salem, USA; 2. Department of Physiology-Pharmacology, Wake Forest University School of Medicine, Winston-Salem, USA; 3. Department of Urology, University of FL College of Medicine – Jacksonville, Jacksonville, USA; 4. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USAShow moreShow less
Source PDF DOI Publisher page
126 days

Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes

Authors
Mingkai Chen; Juan Yang; Jin Wang; Guangrun Du; Lida ZhangShow moreShow less
Affiliations
1. Department of Gastroenterology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China; 2. Department of Gastroenterology, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
160 days

Recent progress of dendritic cell-derived exosomes in tumor immunotherapy

Authors
Baiyan Wang; Yirui Hu; Yujia Zhou; Qianqian Han; Yu Huang; Yuanhang Dong; Yike Zhang; Zixuan Guo; Xuan Zhang; Shuying FengShow moreShow less
Affiliations
1. Medical College, Henan University of Chinese Medicine, Zhengzhou, China; 2. Henan Engineering Research Center for Chinese Medicine Foods for Special Medical Purpose, Zhengzhou, ChinaShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.